ALK and non-small cell lung carcinoma: Updated efficacy and safety results from ALESIA after more than or equal to 5 years of follow-up are consistent with the primary analysis, and with data from the global ALEX study, supporting the finding that 600 mg twice-daily alectinib is effective and well tolerated as a first-line treatment for patients with advanced ALK-positive NSCLC.